Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vita 6 vs Zinc in Autism Spectrum Disorder
NCT07383363Completed
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of pyridoxine and zinc in Autism Spectrum Disorder (ASD) (2 arms). Primary endpoint: Reduction in severity at 3 months. Started Sep 2025; status: completed.
02
Drugs
pyridoxinezinc
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07383363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07383363.